CompletedPhase 4

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

United States122 participantsStarted 2006-08

Plain-language summary

Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Moderate to severe psoriasis involving 3-20% of the body surface area Exclusion Criteria: * Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® Spray or more than 100 grams per week of Taclonex® Ointment * Subjects having psoriasis that involves the scalp, face, or groin

What they're measuring

Overall Disease Severity

Timeframe: End of treatment (Week 4)

Tolerability assessments, incidence of adverse events

Timeframe: Baseline, Weeks 1, 2, 4 and 8

Trial details

NCT IDNCT00437255

SponsorGalderma R&D

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-06

View on ClinicalTrials.gov More Plaque Psoriasis trials